+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 75 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
S

Actively Recruiting

This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.

Age: 18Years +All GendersPhase 2
38 locations
A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
P

Actively Recruiting

Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.

Age: 18Years +All GendersPhase 1
52 locations
S

Actively Recruiting

Researchers are studying BG-C0902, a new antibody-drug conjugate designed to target specific proteins EGFR and MET on advanced solid tumors. This early-phase trial aims to assess the safety, how the drug behaves in the body, and its preliminary effects on tumor activity. The study includes participants with advanced, metastatic, or unresectable solid tumors who have limited treatment options. The study is divided into two parts Phase 1a involves increasing doses of BG-C0902 given alone to find the safe and recommended dose levels. Phase 1b expands on this by evaluating the recommended doses in selected tumor types. BG-C0902 is given by intravenous infusion, and some participants may receive it in combination with other therapies. Participants will undergo regular assessments including safety monitoring, laboratory tests, and tumor measurements. Researchers will track adverse events, dose tolerability, drug levels in the body, and tumor responses over about two years. Tissue samples and imaging will be collected to understand drug effects, with follow-up visits scheduled to monitor long-term outcomes and safety.

Age: 18Years +All GendersPhase 1
15 locations
S

Actively Recruiting

Researchers are evaluating the safety and anti-tumor activity of DZD6008, an oral EGFR inhibitor, in patients with advanced non-small cell lung cancer NSCLC that have EGFR mutations. This Phase 1, open-label, multicenter study is designed to assess the safety, tolerability, pharmacokinetics, and effectiveness of DZD6008 in these patients, including those who have progressed after prior EGFR TKI treatments or are treatment-naive. The trial includes patients with locally advanced or metastatic NSCLC who have confirmed EGFR sensitizing mutations. The study consists of two parts Part A involves dose escalation where patients receive varying daily doses of DZD6008, either as monotherapy or in combination, to evaluate safety and tolerability. Part B focuses on dose expansion, enrolling patients who have either failed one line of third-generation EGFR TKI treatment or are treatment-naive, to assess anti-tumor activity at selected doses. Each treatment cycle lasts 21 days, and dosing continues as per protocol. Participants will undergo regular assessments including tumor measurements based on RECIST 1.1 criteria, blood tests to analyze drug concentration, and monitoring for side effects and overall health status. Safety and anti-tumor activity are evaluated throughout the study, which typically lasts about one year. Researchers also monitor brain metastases status and organ function, ensuring ongoing evaluation of treatment effects and patient well-being during and after the dosing periods.

Age: 18Years +All GendersPhase 1
5 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, how the body processes the drug, and the best dose for a new oral medicine called D3S-002 in adults with advanced solid tumors that have specific mutations in the MAPK pathway. This is a first-in-human trial involving adults with cancers that have progressed despite prior treatments. The study aims to find the recommended dose for future studies and to evaluate the drug as a single treatment or combined with another drug, D3S-001. The study has two main parts Part 1 involves gradually increasing doses of D3S-002 given orally to find a safe dose, while Part 2 includes dose escalation and expansion phases where D3S-002 is given with D3S-001, both administered by mouth. Treatment cycles last 21 days, and participants receive the study drugs daily during these cycles. The study is open-label, meaning both doctors and participants know which treatment is given. Participants will be closely monitored for side effects, how the drugs behave in the body, and tumor response using established criteria. Safety is tracked from the first dose until 30 days after stopping treatment, and dosing effects are followed for up to 24 months. Genetic testing on tumor tissue or blood samples is part of the study, along with regular assessments of organ function, performance status, and disease progression. The study continues until disease progression or other reasons to stop treatment.

Age: 18Years +All GendersPhase 1Phase 2
18 locations

1-10 of 75

1